Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03000283 · ClinicalTrials.gov registry record · Phase 1
Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
A Phase 1 study of Stroke and Intracerebral Hemorrhage, sponsored by Jesse Corry.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03000283 is a Phase 1 study of Stroke and Intracerebral Hemorrhage that has completed, run by Jesse Corry. The registered enrollment target is 7 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03000283, a Phase 1 study of Stroke and Intracerebral Hemorrhage, has completed, sponsored by Jesse Corry.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management. Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.
Conditions Studied
Interventions
- DRUG Conivaptan
Study Locations (1)
Minnesota
- United Hospital - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2019-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03000283
The ClinicalTrials.gov registry entry for NCT03000283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Jesse Corry, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Conivaptan is the first listed.
NCT03000283 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03000283 about?
NCT03000283 is a clinical study titled "Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study". The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A fu...
What is the current status of trial NCT03000283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-03-22. Estimated completion is 2019-04-15.
What conditions does trial NCT03000283 study?
This clinical trial studies the following conditions: Stroke, Intracerebral Hemorrhage, Cerebral Edema, Cerebral Hemorrhage.
What interventions are being tested in trial NCT03000283?
The interventions under investigation include: Conivaptan (DRUG).
Who is sponsoring clinical trial NCT03000283?
This trial is sponsored by Jesse Corry, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03000283 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
Hybrid Robot+FES Stroke Rehabilitation
RECRUITING · Phase 1
-
Vibrotactile Stimulation for Upper-Extremity Stroke Rehabilitation
RECRUITING · Phase 1
-
Facilitating Neuroplastic Changes of Acute Stroke Survivors
RECRUITING · Phase 1
-
Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke
RECRUITING · Phase 1
-
Accelerated rTMS vs. Sham for Stroke Apathy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.